Alkermes Plc (ALKS) revenue breakdown

Healthcare · Drug Manufacturers - Specialty & Generic · Market cap $6.5B

By product, Product sales, net is the largest at 80% of fiscal 2025 revenue, growing 19% a year over 9 years.

By region, U.S. is the largest at 93% of fiscal 2025 revenue, growing 11% a year over 9 years.

Revenue by product

Fiscal years, as Alkermes Plc reports them in its 10-K filings; fiscal 2025 total $1.5B.

Products2016201720182019202020212022202320242025Share
Product sales, net$256M$363M$450M$524M$552M$627M$778M$920M$1.1B$1.2B 80%
Manufacturing and royalty revenues$487M$505M$527M$448M$484M$542M$332M$743M$474M$291M 20%
Research and development revenue$2M$7M$69M$53M$2M$1M$260,000$19,000$3,000— —
License revenue—$28M$48M$146M$1M$4M———— —
License revenue——————$2M——— —

Revenue by region

Fiscal years, as Alkermes Plc reports them in its 10-K filings; fiscal 2025 total $1.5B.

Regions2016201720182019202020212022202320242025Share
U.S.$557M$700M$885M$967M$839M$984M$932M$1.5B$1.4B$1.4B 93%
Rest of world$184M$194M$205M$201M$197M$187M$178M$170M$146M$102M 7%
Ireland$4M$10M$5M$3M$3M$2M$2M$1M$1M$754,000 0%
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ALKS.
Open ALKS in Investingly

Questions

Where does Alkermes Plc make its money?

In fiscal 2025, by product: Product sales, net $1.2B, Manufacturing and royalty revenues $291M.

From Alkermes Plc's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.